Table 1 Comparisons of patients’ clinical characteristics between the aBVA and VAB cohorts
Variable | Total (n = 301) | aBVA cohort (n = 109) | VAB cohort (n = 192) | P |
|---|---|---|---|---|
Age [years, median (range)] | 62 (30–83) | 62 (35–81) | 62 (30–83) | 0.966 |
Female [cases (%)] | 186 (61.8) | 65 (59.6) | 121 (63.0) | 0.561 |
Smoker [cases (%)] | 101 (33.6) | 39 (35.8) | 62 (32.3) | 0.538 |
Neoadjuvant therapy [cases (%)] | 13 (4.3) | 4 (3.7) | 9 (4.7) | 0.775* |
Histological subtype [cases (%)] | ||||
 Adenocarcinoma | 248 (82.4) | 98 (89.9) | 150 (78.1) | 0.033 |
 Squamous cell carcinoma | 37 (12.3) | 7 (6.4) | 30 (15.6) |  |
 Others | 16 (5.3) | 4 (3.7) | 12 (6.3) |  |
TNM stage [cases (%)] | 0.539* | |||
 I | 209 (69.4) | 80 (73.4) | 129 (67.2) |  |
 II | 42 (14.0) | 12 (11.0) | 30 (15.6) |  |
 III | 44 (14.6) | 16 (14.7) | 28 (14.6) |  |
 IV | 6 (2.0) | 1 (0.9) | 5 (2.6) |  |